19:35 , Dec 6, 2016 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Lipodystrophy Mouse and cell culture studies suggest inhibiting GPAT3 and/or GPAT4 could help treat congenital generalized lipodystrophy type 2, which is caused by mutations in BSCL2. In a mouse model of the disease, levels of...